Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Return on Sales (2017 - 2025)

Akebia Therapeutics (AKBA) has disclosed Return on Sales for 9 consecutive years, with 0.21% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 28.0% to 0.21% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.02% through Dec 2025, up 41.0% year-over-year, with the annual reading at 0.02% for FY2025, 41.0% up from the prior year.
  • Return on Sales for Q4 2025 was 0.21% at Akebia Therapeutics, down from 0.01% in the prior quarter.
  • The five-year high for Return on Sales was 73.7% in Q2 2022, with the low at 58.68% in Q4 2021.
  • Average Return on Sales over 5 years is 0.13%, with a median of 0.51% recorded in 2024.
  • The sharpest move saw Return on Sales skyrocketed 7529bps in 2022, then plummeted -7390bps in 2023.
  • Over 5 years, Return on Sales stood at 58.68% in 2021, then soared by 96bps to 2.17% in 2022, then surged by 83bps to 0.38% in 2023, then crashed by -31bps to 0.49% in 2024, then soared by 57bps to 0.21% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 0.21%, 0.01%, and 0.0% for Q4 2025, Q3 2025, and Q2 2025 respectively.